Form 4: Surgery Partners Director Acquires Over 6,800 Shares in Equity Grant

Teresa DeLuca, a Director at Surgery Partners, Inc. (SGRY), acquired 6,861 shares of common stock at $23.32 per share, increasing her direct beneficial ownership to 65,191 shares, with vesting scheduled for June 2026.

Summary

• Teresa DeLuca, a Director of Surgery Partners, Inc. (SGRY), acquired 6,861 shares of the company's common stock.
• The transaction occurred on June 10, 2025, with an acquisition price of $23.32 per share.
• Following this acquisition, Ms. DeLuca's direct beneficial ownership in Surgery Partners, Inc. increased to a total of 65,191 shares.
• The newly acquired 6,861 shares are restricted and are scheduled to vest on June 10, 2026.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director is generally a positive indicator of insider confidence. However, as it appears to be a routine equity compensation grant rather than an open market purchase, its impact on overall sentiment is moderately positive but not highly significant.

Positives

• The acquisition of additional shares by a director (Teresa DeLuca) can be interpreted as a positive signal, indicating confidence in the company's future performance and strategic direction.
• This transaction further aligns the director's financial interests with those of the company's shareholders, as the value of her compensation is tied to the stock's performance.

Risks

• The acquired shares are restricted and will not vest until June 10, 2026, meaning the director's ability to fully realize the value of these shares is contingent on the company's stock performance over the next year.

Future Outlook

The document indicates that the acquired shares are part of an equity compensation plan, with a future vesting date of June 10, 2026. This ties the director's future compensation directly to the company's stock performance until that date.

Industry Context

This Form 4 filing details a routine insider transaction within the healthcare services industry, specifically for Surgery Partners, Inc. It reflects common practices of providing equity compensation to board members to align their interests with shareholders, a widespread trend across publicly traded companies in various sectors.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries, including healthcare.
• The practice of granting restricted stock to directors as part of their compensation package is a common corporate governance mechanism aimed at aligning the interests of board members with long-term shareholder value, consistent with industry standards for executive and director compensation.

Related Party Transactions

• The acquisition of shares by a director is a related party transaction, representing equity compensation granted by the company to an insider.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively by shareholders as it increases the director's stake in the company, potentially signaling confidence and aligning interests.

Next Steps

• The 6,861 acquired shares will vest on June 10, 2026, at which point they will become fully owned by the director.

Key Dates

Keywords

Surgery Partners, SGRY, Form 4, Insider Transaction, Director, Stock Acquisition, Equity Compensation, Restricted Stock, Teresa DeLuca